Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

M. Stein, Eytan; D. DiNardo, Courtney; T. Fathi, Amir; S. Mims, Alice; W. Pratz, Keith; R. Savona, Michael; S. Stein, Anthony; M. Stone, Richard; S. Winer, Eric; S. Seet, Christopher; Döhner, Hartmut; A. Pollyea, Daniel; McCloskey, James; Odenike, Olatoyosi; Löwenberg, Bob; J. Ossenkoppele, Gert; A. Patel, Prapti; Roshal, Mikhail; G. Frattini, Mark; Lersch, Frederik; Franovic, Aleksandra; Nabhan, Salah; Fan, Bin; Choe, Sung; Wang, Hongfang; Wu, Bin; Hua, Lei; Almon, Caroline; K. Cooper, Michael; M. Kantarjian, Hagop; S. Tallman, Martin

doi:10.1182/blood.2020007233

Public

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Published in Blood • Oct 7, 2020

Authors:

Eytan M. Stein

Courtney D. DiNardo

Amir T. Fathi

Abstract

Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia (AML), this phase 1 study evaluated the safety and...

Subject

Medicine

Myeloid leukemia

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!